low-dose medicine Naltrexone has been shown to help heroin and alcohol addicts kick the habit. But, in much smaller doses, it holds tremendous promise in treating autoimmune disorders
By Dr Craige GoldingMBChB (Cum Laude), FCP(SA), ABAARM, FAARM, ACAM-Certified Chelation Therapist, FICT, MS (Magna Cum Laude), NUGO-certifiedT
endorphins the body produces. This deficiency worsens
over time as the body becomes more and more dependant
IMMUNE REGULATOR
to its ability to “block out” endorphins
making them immune to the euphoric effects of heroin.2
INNER PAINKILLER
In 1985, a US doctor by the name of Dr Bernard Bihari
If you’re an athlete or a body builder, you’ve probably heard
tried naltrexone with more than 50 heroin addicts who had
of endorphins. These are the body’s natural painkillers and
stopped using the drug, but the side effects at that dose
are secreted whenever parts of your body are injured or
were unbearable.3 Then, later that year, a large number of
placed under stress. Endorphins have a euphoric effect
heroin addicts became sick with AIDS, which prompted
on the brain, described as a “runner’s high”, which is felt
Dr Bihari and his colleagues to shift their focus to this disease
during or directly after a heavy bout of exercise. This occurs
and to ways of strengthening the patients’ immunity.
because the endorphins stimulate specialised cells in the
Since endorphins are the hormones centrally involved in
supporting and regulating the immune system, Dr Bihari’s
These cells are also sensitive to “external” painkillers, such
team measured levels of endorphins in the blood of AIDS
as morphine and heroin. Alcohol, on the other hand, affects
patients and found them to be less than 20% of normal.
the opioid receptors indirectly, because it stimulates the
He knew that when naltrexone is administered, it first
production of other types of internal opioids.1 The more
stimulates the body to produce more endorphins. But if the
external stimulation the opioid receptors receive, the less
dosage is too high, the effects are blocked. Dr Bihari found
H I G H HOP E S F OR L O W - D O S E M E D I C I N E
that with lower doses – a fraction of those given to addicts
horizon for those suffering from autoimmune disorders,
– which are taken at night when the body’s own production
albeit in the form of a medicine not initially created for
of endorphins is highest, the blockage doesn’t occur.4
that purpose. It is, however, no magical cure-all, and an integrative and comprehensive approach to autoimmune
WEAKENED DEFENCES
conditions is still the best treatment route. HI
Autoimmune conditions are confusing because they’re often assumed to be caused by an overly strong immune
IMMUNE-BOOSTING PROTOCOL
system. This isn’t the case. Underlying these conditions, is an immune system that's poorly regulated.5 The immune cells,
or lymphocytes, then fail to distinguish between foreign
invading organisms and the body’s own cells, and when the
Krill oil (1,000mg) or fish oil omega-3 (2,000mg daily)
immune system begins to attack, it triggers the widespread
inflammation and scarring seen in the affected parts.
In autoimmune patients, low-dose naltrexone (LDN)
works by restoring endorphin levels to normal, thereby
allowing the immune system to resume its usual function.
Many studies have shown that an immunodeficiency is a
Low-dose naltrexone (on prescription).
characteristic of autoimmune diseases, including multiple
References
sclerosis, rheumatoid arthritis, Crohn’s disease and chronic
1 Sinclair JD. Evidence about the use of naltrexone and for different ways of using it
in the treatment of alcoholism. Alcohol and Alcoholism. 2001;36(1):2-10
fatigue syndrome.6,7,8 There are even studies suggesting that
2 Shader RI. Antagonists, Inverse Agonists, and Protagonists. Journal of Clinical
Psychopharmacology. Aug 2003;23(4):321-22
LDN’s role of modulating immune function may eventually
3 Kokayi KB. Dr Kamau B Kokayi Interviews Dr Bihari. Global Medicine Review. 2003.
www.lowdosenaltrexone.org/gazorpa/interview.html
play a role in disease prevention, rather than treatment.9
4 Bihari B, Drury FM, et al. Low Dose Naltrexone in the Treatment of Acquired
Immune Deficiency Syndrome. Oral Presentation at the IV International AIDS
One of the most promising and recent results, however,
5 Buckley RH. Primary Immunodeficiency Diseases Due to Defects in Lymphocytes.
comes from a study that looked at the effects of LDN on
6 Thewissen M, Linsen L, et al. Premature immunosenescence in rheumatoid
people who suffer from Crohn’s disease, an autoimmune
arthritis and multiple sclerosis patients. Ann N Y Acad Sci. Jun 2005;1051:255-62
7 Marks DJ, Harbord MW, et al. Defective acute inflammation in Crohn’s disease: a
inflammatory condition of the bowel.10 After 12 weeks,
clinical investigation. Lancet. Feb 2006;367(9511):668-78
8 Vernon SD, Reeves WC. The chal enge of integrating disparate high-content data:
as many as 78% of those treated with LDN experienced a
epidemiological, clinical and laboratory data col ected during an in-hospital study of chronic fatigue syndrome. Pharmacogenomics. Apr 2006;7(3):345-54
dramatic decline in the severity of their symptoms, while
9 Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of
life. Med Hypotheses. Mar 2009;72(3):333-7
33% were in complete remission. With dramatic results such
10 Smith JP, Bingaman SI, et al. Therapy with the Opioid Antagonist Naltrexone
Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-
as these to encourage further research, there’s hope on the
Control ed Trial. Dig Dis Sci. 8 Mar 2011. www.ncbi.nlm.nih.gov/pubmed/21380937
Jakobikirchhof 920095 HamburgTel. 0 40-33 09 09Fax 0 40-33 57 44E-Mail: jungck.hh@t-online.deInternet: vdaea.de PRESSEMITTEILUNG Zum Verhalten einiger Krankenkassen bei „off-label-Verordnung“ für Schmerzpatienten Das Bundessozialgericht (AZ B I KR 37/00) hat kürzlich entschieden, daß Medikamente außerhalb des Anwendungsbereiches, auf das sich die Zu- lassung erstreckt, nicht bz
Formerly Aw l W eave Ghat The Newsletter of the American Association on Intellectual and Developmental Disorders’ (AAIDD) Humanist Action Group – December, 2007 v.1 issue 4 This newsletter expresses the opinion of this subgroup and not necessarily of AAIDD All data presented are opinions and alternative opinions may be printed in later issues. Send feedback and submissions